Finerenone in patients with CKD and T2D with and without heart failure: A prespecified subgroup analysis of the FIDELIO-DKD trial

PMID: 35239204 DOI: 10.1002/ejhf.2469

The effects of finerenone on cardiorenal outcomes in patients with chronic kidney disease and type 2 diabetes were compared in this prespecified analysis of the FIDELIO-DKD trial. The patients (none of whom had symptomatic HFref) were treated with optimised renin-angiotensin system blockade and were randomised to finerenone or placebo.


LinkedIn